68th Annual Scientific Sessions of the American College of Cardiology 2019
ODYSSEY OUTCOMES: Lipoprotein(a) analysis: News round-up from ACC.19
In a clinical late breaking session, this year’s Congress highlighted a subgroup analysis from ODYSSEY OUTCOMES, focusing on the role of elevated lipoprotein(a) [Lp(a)] as a contributor to cardiovascular event reduction with alirocumab.1 PCSK9 Forum Editor Jane Stock reports from ACC.19 To recap, ODYSSEY OUTCOMES…
read more »
More insights from ODYSSEY OUTCOMES: News round-up from ACC.19
Why clinicians need to consider polyvascular disease Another analysis from ODYSSEY OUTCOMES focused on patients with atherosclerosis evident in more than one vascular bed. Patients were categorized according to the presence of polyvascular disease in two beds (coronary and peripheral artery or cerebrovascular disease, n=…
read more »
What was the PCSK9 news at this year’s Congress? News round-up from ACC.19
Lipoprotein(a) and plaque Patients with higher higher lipoprotein(a) [Lp(a)] levels had more atherosclerotic plaque, especially with concomitant elevated LDL cholesterol levels, according to this analysis from Japan. In total, 255 consecutive patients with stable coronary artery disease underwent optical coherence tomography imaging of culprit lesions….
read more »
